Get started
Author

Ellen Michelle Diament Hooper

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2022 · Timothy A. Yap, Justin F. Gainor, et al. · Clinical Cancer Research · 82
PDF
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
2018 · Timothy Anthony Yap, Howard A. Burris, et al. · Journal of Clinical Oncology · 30
Diagnosis of a rare fetal haemoglobinopathy in the age of next-generation sequencing
2016 · Thomas A Hooven, Ellen M Hooper, et al. · BMJ Case Reports · 8
Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
2021 · Oleh Kobziev, Iurie Bulat, et al. · Journal of Clinical Oncology · 6
Abstract CT189: Improved progression-free and overall survival (PFS/OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial
2019 · Timothy Anthony Yap, Justin F. Gainor, et al. · Cancer Research · 2
Abstract 463: Preclinical evaluation of CNS drug penetration of a novel series of MTA-cooperative PRMT5 inhibitors including TNG456
2025 · Alice Tsai, Charles B. Davis, et al. · Cancer Research · 1
Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors
2024 · Matthew R. Tonini, Andre A. Mignault, et al. · Cancer Research · 1
Singers, Scores and Sounds
2022 · Ellen Hooper · Routledge eBooks · 1
Abstract 5536: ICOS hi CD4 T cells emerging on vopratelimab treatment have Th1 central memory characteristics and may contribute to durability of clinical responses
2020 · Amadna Hanson, Abha Daneshwar, et al. · Cancer Research · 1
Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial.
2020 · Timothy A Yap, Justin F. Gainor, et al. · Journal of Clinical Oncology · 1
QoL of pediatric-inspired compared to hyper-CVAD regimens for newly diagnosed AYA patients with Ph-ALL: A modeling analysis.
2017 · Ellen Hooper, Xingdi Hu, et al. · Journal of Clinical Oncology · 1
Burden of cytopenias among myelofibrosis patients.
2016 · Joseph Feliciano, Yoojung Yang, et al. · Journal of Clinical Oncology · 1
EXTH-32. Preclinical evaluation of the CNS penetration of a novel series of MTA-cooperative PRMT5 inhibitors including TNG456
2025 · Alice Tsai, Charles Davis, et al. · Neuro-Oncology
PDF
Abstract 4608: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitors
2025 · Kimberly J. Briggs, Andre Mignault, et al. · Cancer Research
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
PDF
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
2023 · Timothy A. Yap, Justin F. Gainor, et al.
Works count: 42
Citation count: 135
H-index: 4
I10-index: 2
Year
Topic
Type